Editorial: Cutaneous immunology
- PMID: 37692788
- PMCID: PMC10484560
- DOI: 10.3389/fmed.2023.1275332
Editorial: Cutaneous immunology
Keywords: alopecia areata; bullous pemphigoid; cutaneous immunology; dupilumab; immunotherapy; inflammation; prurigo nodularis.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic Cutaneous immunology
Similar articles
-
Bullous pemphigoid and prurigo nodularis.J Am Acad Dermatol. 1986 May;14(5 Pt 2):944-7. doi: 10.1016/s0190-9622(86)70117-5. J Am Acad Dermatol. 1986. PMID: 3519701
-
Dupilumab: A Review of Present Indications and Off-Label Uses.J Investig Allergol Clin Immunol. 2022 Apr 19;32(2):97-115. doi: 10.18176/jiaci.0682. Epub 2021 Mar 3. J Investig Allergol Clin Immunol. 2022. PMID: 33661102 Review.
-
Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.J Dermatolog Treat. 2021 Feb;32(1):19-28. doi: 10.1080/09546634.2019.1689227. Epub 2019 Nov 12. J Dermatolog Treat. 2021. PMID: 31693426
-
Bullous and Nonbullous Pemphigoid Associated With Prurigo Nodularis: Successful Treatment With Dupilumab.Int J Dermatol. 2025 Jul 2. doi: 10.1111/ijd.17922. Online ahead of print. Int J Dermatol. 2025. PMID: 40605187 No abstract available.
-
The emerging role of dupilumab in dermatological indications.Expert Opin Biol Ther. 2021 Nov;21(11):1461-1471. doi: 10.1080/14712598.2021.1907341. Epub 2021 Mar 30. Expert Opin Biol Ther. 2021. PMID: 33769900